Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA-Adverse event reporting system (FAERS) database
Crossref DOI link: https://doi.org/10.1007/s11096-021-01273-8
Published Online: 2021-06-09
Published Print: 2021-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Guo, Mingxing
Thai, Sydney
Zhou, Junwen
Wei, Jingkai
Zhao, Ying
Xu, Wanyi
Wang, Tiansheng
Cui, Xiangli
Text and Data Mining valid from 2021-06-09
Version of Record valid from 2021-06-09
Article History
Received: 12 September 2020
Accepted: 26 April 2021
First Online: 9 June 2021